Download Free Sample Report

The "Global Gene Therapy in Cardiovascular Disorder Market" was valued at US$ 99.00 million in 2024 and is predicted to reach US$ 278.31 million by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 18.8% during the forecast period (2024-2030).

Gene therapy for cardiovascular disorders is a cutting-edge therapeutic approach that involves the delivery, modification, or replacement of genes within cardiovascular tissues to treat or prevent heart and vascular diseases. This innovative method aims to address the underlying genetic or molecular causes of various cardiovascular conditions, which can range from congenital heart defects and ischemic heart disease to heart failure and arrhythmias.

Key components of gene therapy in cardiovascular disorders:

1. Mechanism:

   • Gene therapy utilizes vectors, often modified viruses (such as adenoviruses, lentiviruses, or adeno-associated viruses), to deliver therapeutic genes directly to heart or blood vessel cells.
   • The main objectives include:
     • Gene replacement: Introducing a healthy copy of a gene that is mutated or missing.
     • Gene editing: Using techniques like CRISPR to modify or correct dysfunctional genes.
     • Gene silencing: Reducing the expression of harmful genes that contribute to cardiovascular disease.

2. Targets and Strategies:

   • Vascular diseases: Gene therapy may be employed to promote the growth of new blood vessels (angiogenesis) in conditions such as peripheral artery disease (PAD) or myocardial ischemia, where blood flow is restricted.
   • Heart failure: Gene therapies can aim to enhance the contractility of heart muscles or improve their ability to regenerate.
   • Genetic cardiomyopathies: Conditions such as hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM) can potentially be treated by correcting genetic mutations.
   • Atherosclerosis: Gene therapies might target the reduction of cholesterol levels or the inflammation in arterial walls.

3. Advantages:

   • Targeted treatment: Gene therapy can directly address the genetic basis of cardiovascular disorders, offering a more precise treatment option than conventional therapies that mainly manage symptoms.
   • Long-lasting effects: A single gene therapy administration can lead to sustained therapeutic effects by permanently altering gene expression or cellular function.
   • Regeneration: Gene therapy has the potential to promote tissue repair and regeneration, which is especially beneficial for damaged heart tissues.

4. Challenges:

   • Delivery to target tissues: Ensuring effective delivery of therapeutic genes to the heart and vascular system poses challenges, particularly in overcoming the barriers to accessing heart tissues.
   • Immune response: There is a risk of immune reactions against the vectors or the newly introduced proteins, which could diminish the efficacy of the therapy.
   • Long-term effects: The long-term safety and efficacy of gene therapy in cardiovascular patients are still under investigation, requiring extensive clinical trials.

Applications in cardiovascular disorders:

• Ischemic Heart Disease: Gene therapies are being studied to enhance angiogenesis and improve blood flow in heart tissues deprived of oxygen.
• Heart Failure: Strategies are being developed to improve cardiac function by introducing genes that promote muscle contraction or protect against cell death.
• Inherited Cardiovascular Conditions: Gene therapy holds promise for correcting genetic mutations that lead to conditions like familial hypercholesterolemia or arrhythmogenic right ventricular cardiomyopathy.

Gene therapy for cardiovascular disorders represents a promising frontier in medical research, with the potential to significantly improve treatment outcomes for patients with various heart and vascular diseases. As research advances, it may lead to more effective and targeted therapies that address the root causes of these conditions.

The global key manufacturers of Gene Therapy in Cardiovascular Disorder include Renovacor, Gene Biotherapeutics, AskBio, Human Stem Cells Institute and Novartis, etc. in 2023, the global top five players have a share approximately % in terms of revenue.

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

This report aims to provide a comprehensive presentation of the global market for Gene Therapy in Cardiovascular Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy in Cardiovascular Disorder. This report contains market size and forecasts of Gene Therapy in Cardiovascular Disorder in global, including the following market information:

• Global Gene Therapy in Cardiovascular Disorder Market Revenue, 2019-2024, 2025-2030, ($ millions)
• Global top five companies in 2023 (%)

We has surveyed the Gene Therapy in Cardiovascular Disorder companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Gene Therapy in Cardiovascular Disorder Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Gene Therapy in Cardiovascular Disorder Market Segment Percentages, by Type, 2023 (%)

• Viral Gene Therapy
• Non-viral Gene Therapy

Global Gene Therapy in Cardiovascular Disorder Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Gene Therapy in Cardiovascular Disorder Market Segment Percentages, by Application, 2023 (%)

• Heart Disease
• Vascular Disease

Global Gene Therapy in Cardiovascular Disorder Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Gene Therapy in Cardiovascular Disorder Market Segment Percentages, By Region and Country, 2023 (%)

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Gene Therapy in Cardiovascular Disorder revenues in global market, 2019-2024 (estimated), ($ millions)
• Key companies Gene Therapy in Cardiovascular Disorder revenues share in global market, 2023 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Renovacor
• Gene Biotherapeutics
• AskBio
• Human Stem Cells Institute
• Novartis

Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy in Cardiovascular Disorder, market overview.
Chapter 2: Global Gene Therapy in Cardiovascular Disorder market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy in Cardiovascular Disorder company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy in Cardiovascular Disorder in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.